4971 results for "Psychedelics"
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
Canadian Journal of Health Technologies – June 24, 2021
Summary
Psychedelics show significant potential in medicine, improving mental health symptoms with no serious adverse events. One randomized controlled trial found psilocybin-assisted psychotherapy efficacious for mood disorders like depression. Across two systematic reviews and three randomized controlled trials, various hallucinogens, including MDMA, combined with psychotherapist support, demonstrated clinical effectiveness for conditions like anxiety. This growing area in clinical psychology and psychiatry, part of broader drug studies, explores how these compounds, often from chemical synthesis, influence behavior. Sample sizes were typically under 20, warranting further investigation.
Abstract

 Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations o...
Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?
Journal of Psychedelic Studies – June 01, 2020
Summary
Current treatments for depression often fall short. Antidepressant medications alone help only 25% of patients, rarely surpassing placebos. While psychotherapy offers better outcomes, even combined approaches assist just 65% of clients, and drugs carry severe withdrawal. Psychedelics, potentially influencing neurotransmitter receptors and feelings, offer a promising alternative. Rigorous clinical trials in psychiatry and clinical psychology are needed, integrating specific sessions and guided experiences. This approach, incorporating principles of chemical synthesis, could have an unparalleled public health impact, advancing beyond current antidepressant drug studies.
Abstract
Abstract Despite the popular support for psychedelics as aids for depression, academics and the public frequently overestimate the efficacy of avai...
"Facing Death. . . Now, That's a Serious Thing to Confront" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.
Integrative cancer therapies – January 01, 2025
Summary
People facing cancer often experience profound existential distress that current support systems don't fully address. This study investigated how patients perceive psychedelic-assisted therapy (PAT) as a novel approach for cancer-related psychosocial symptoms. Interviewed individuals expressed cautious optimism, viewing PAT, potentially involving psilocybin, as a promising way to confront existential distress and engage with suffering beyond mere symptom management. Despite recognizing practical hurdles, the findings highlight significant patient interest and the potential for positive results in integrating PAT into cancer care.
Abstract
People living with cancer (PLWC) often face profound existential distress that is insufficiently addressed by conventional psychosocial supports. T...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care
Journal of Hospice and Palliative Nursing – December 19, 2024
Summary
Psychedelic-assisted therapy shows initial promise for addressing profound psycho-spiritual-existential distress in palliative care. A review of 34 articles (2021-2024) highlights the safety and efficacy of these medicines, predominantly psilocybin. Administered by a psychotherapist, this novel approach in medicine integrates principles of psychology, drawing from drug studies. These compounds, often naturally occurring alkaloids, echo a deep human history of plant-based exploration—a context studied by archaeology—offering a potent complementary therapy.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Psychedelic-assisted psychotherapy: Where is the psychotherapy research?
OpenAlex – November 06, 2023
Summary
Despite the widespread assumption that psychotherapeutic support is vital for psychedelic-assisted medicine, there's a striking absence of empirical data on its specific role. As clinical trials for these compounds, influencing neurotransmitter receptors, transition to evaluating efficacy for mental health, understanding the psychotherapist's role in this intervention becomes paramount. Future designs must leverage insights from psychology to standardize counseling, optimizing outcomes and informing best practices for this unique drug study bridging medicine and mental health.
Abstract
Rationale: Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for mental health conditions, such as substance use disord...
The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?
Cureus – October 31, 2022
Summary
Despite standard psychotherapy, posttraumatic stress often persists, contributing to chronic medical and psychiatry issues. This urgent challenge in clinical psychology is spurring new drug studies into psychedelics. Examining chemical synthesis and alkaloids, including cannabis, ketamine, and classical psychedelics, the review explores their potential to alleviate traumatic stress. These substances may influence neurotransmitter receptor activity, offering a novel approach where traditional medicine struggles. The historical context, even from archaeology, is considered alongside current evidence for these promising psychedelic therapies, aiming to improve patient outcomes.
Abstract
Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputab...
Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis.
Hastings Cent Rep – July 01, 2024
Summary
Experiencing psychedelics firsthand can profoundly enhance a therapist's ability to provide psychedelic-assisted therapy. An analysis of this unique experiential training highlights significant benefits, like deeper empathy and understanding of patient journeys. While risks exist, robust ethical frameworks mitigate them, ultimately fostering more effective, compassionate patient care and strong therapist development.
Abstract
Experiential Training in Psychedelic-Assisted Therapy: A Risk-Benefit Analysis.
The “Third” Eye: Ethics of Video Recording in the Context of Psychedelic-Assisted Therapy
Canadian Journal of Bioethics – December 07, 2023
Summary
Ensuring patient safety in psychedelic therapy is crucial, but mandatory video recording introduces complex ethical challenges. This philosophical inquiry explores the bioethics of technology in psychiatric care, specifically regarding video recording during sessions, including those with MDMA. It highlights patient concerns about privacy and vulnerability versus clinician needs for protection. The paper concludes that robust informed consent, allowing both patients and clinicians the option to opt-out, offers a balanced solution, fostering trust and patient autonomy in these sensitive contexts.
Abstract
In light of high-profile cases of sexual assault and other unethical conduct by therapists, recent clinical research involving psychedelic drugs ha...
Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Psychedelic-assisted therapy shows promising results in treating moral injury - psychological trauma from events that violate one's core values. Studies examining MDMA, psilocybin, and LSD combined with psychotherapy reveal significant improvements in self-compassion, forgiveness, and PTSD symptoms. The treatments particularly help those struggling with trauma-related moral conflicts and self-acceptance.
Abstract
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery ...
(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – March 01, 2022
Summary
Unexpectedly, a novel compound class, APBTs, influences brain chemistry without causing stimulant effects. Researchers investigated these sulfur-based analogs, finding they inhibit monoamine reuptake and release neurotransmitters, similar to MDMA. Despite this, they didn't induce hyperactivity in mice. Instead, these compounds activated serotonin receptors, producing psychedelic-like effects, evident by specific behavioral responses. This distinct profile, with strong psychedelic activity and minimal stimulation, suggests potential for therapeutic applications, such as in drug-assisted psychotherapy.
Abstract
Derivatives of (2-aminopropyl)indole (API) and (2-aminopropyl)benzofuran (APB) are new psychoactive substances which produce stimulant effects in v...
A Cross-Sectional Survey Investigating Māori and Non-Māori Cancer Patients' Views on Psychedelic-Assisted Therapy in Aotearoa New Zealand.
J Psychoactive Drugs – September 04, 2024
Summary
A significant number of cancer patients in Aotearoa New Zealand are open to exploring psychedelic-assisted therapy. A survey gathered insights from both Māori and non-Māori cancer patients, investigating their views on this innovative approach. Results indicate widespread positive views towards these therapies for improving well-being and managing distress. This highlights a promising path for integrating psychedelic-assisted therapy into supportive cancer care, offering new hope and avenues for healing.
Abstract
A Cross-Sectional Survey Investigating Māori and Non-Māori Cancer Patients' Views on Psychedelic-Assisted Therapy in Aotearoa New Zealand.
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Frontiers in Psychiatry – January 20, 2022
Summary
MDMA-assisted therapy, a compelling development in Psychedelic Medicine, is in phase-3 FDA clinical trials for PTSD, designated a "breakthrough therapy" in 2017. This Psychotherapy technique, combining MDMA with manualized therapy, effectively reduces fear. Psychology and Psychiatry are now exploring its potential to address trauma from chronic race-based experiences among Black, Indigenous, and other People of Color. This perspective from Drug Studies emphasizes the ethical need for culturally competent psychotherapists, expanding Psychotherapy Techniques and Applications, and offering new Academic and Historical Perspectives in Psychology.
Abstract
Psychedelic medicine is an emerging field that examines entheogens, psychoactive substances that produce non-ordinary states of consciousness (NOSC...
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Frontiers in Neuroscience – September 20, 2021
Summary
Psychedelics might profoundly enhance adult brain plasticity, akin to "reopening" specific critical periods of development. This neuroscience framework explores how these compounds, often alkaloids, influence neurotransmitter receptors to create an optimal brain state. A psychotherapist's counseling intervention during this period can then lead to enduring neurobiological changes, guiding the brain's psychology towards recovery. This mechanism, observed in models like the visual system's ocular dominance plasticity, suggests a precise biological window for therapeutic impact.
Abstract
As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized...
Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.
Drug Alcohol Depend Rep – March 16, 2022
Summary
Many marginalized women in Canada show strong interest in psychedelic-assisted therapy. Researchers explored this desire within a community, finding many seek new mental health solutions. These women, often with trauma histories, see potential benefits. The findings highlight a clear demand for accessible, culturally sensitive psychedelic care, emphasizing its positive potential for vulnerable populations.
Abstract
Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.
[The nursing role in psychedelic-assisted psychotherapy].
Revue de l'infirmiere – January 01, 2024
Summary
Nurses play a vital role in the emerging field of psychedelic-assisted psychotherapy, serving as essential guides through patients' transformative experiences with substances like psilocybin and LSD. Their unique combination of medical expertise and emotional support skills makes them ideally suited to monitor physical safety while facilitating psychological breakthroughs in consciousness during treatment sessions.
Abstract
In this article, we aim to highlight the specific role of nurses in the interdisciplinary model of psychedelic-assisted psychotherapy. We argue tha...
Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study
Journal of Psychoactive Drugs – June 23, 2025
Summary
Dutch mental health professionals largely embrace psychedelic-assisted psychotherapy, a promising development in mental health care. A cross-sectional study of 198 clinicians revealed positive attitudes toward treatments using compounds like MDMA and psilocybin. This exploratory research in psychology found attitudes correlated with prior personal use of these natural compound pharmacology studies. Psychotherapists believe psychiatrists and clinical psychologists are ideal administrators, preferring specialized hospital settings within medicine. While supporting psychedelics and drug studies, including chemical synthesis and alkaloids, concerns persist about connecting with patients during altered states.
Abstract
Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated fo...
Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample
OpenAlex – February 28, 2025
Summary
Individuals with high lifetime involvement in psychedelic-assisted therapy (PAT) report elevated depression and anxiety, a compelling finding from a cross-sectional study. Analyzing a nonprobability sample of 244 PAT patients, a latent class model identified three groups: High-PAT (55.7%), Medium-PAT (29.1%), and a unique Psilocybin-Ketamine class (15.2%). This psychology-focused research suggests a link between extensive PAT engagement and mental health challenges, informing clinical psychology, medicine, and psychiatry regarding these psychedelics.
Abstract
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional ...
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
OpenAlex – August 25, 2024
Summary
A systematic review of 21 randomized trials (N=1034) reveals a stark lack of diversity in promising psychedelic-assisted therapies. Only 12.2% of participants were Black/African-American and 7.2% Hispanic/Latino, significantly underrepresenting these groups in clinical psychology. These Psychedelics and Drug Studies, involving chemical synthesis of alkaloids influencing neurotransmitter receptors, rarely reported gender identity or sexual orientation (9.5%). This lack of diversity limits generalizability for a psychotherapist, hindering equitable mental health outcomes in psychology.
Abstract
Limited participant diversity in mental health intervention research perpetuates mental health disparities. This issue has become a particularly sa...
Transformative experience and informed consent to psychedelic-assisted psychotherapy
Frontiers in Psychology – May 26, 2023
Summary
A profound ethical dilemma arises for **informed consent** in psychedelic-assisted psychotherapy. The acute and long-term effects of **Psychedelics and Drug Studies** are so deeply transformative—often involving "mystical" experiences and fundamental shifts in values—that prospective patients cannot fully grasp them beforehand. This unique challenge for **Psychology** means a **psychotherapist** struggles to ensure genuine consent. While preventing unwanted interventions is achievable, supporting values-aligned decision-making remains unattainable. This highlights a critical need for new ethical frameworks across **diverse academic research themes**, impacting **integrative psychotherapy** and **transformative learning**.
Abstract
Just as psychedelic-assisted psychotherapy (PAP) represents a clinical innovation that may need to be accommodated with corresponding theoretical a...
Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature
BMC Psychiatry – July 31, 2018
Summary
Psychedelic-assisted psychotherapy shows promise for mental health treatment, yet minorities remain significantly underrepresented in these studies. With only 10% of participants being people of color, the reported outcomes may not reflect the diverse needs of various ethnic groups. Enhancing inclusion and recruitment strategies is crucial to ensure that Indigenous populations and other minority groups can access these therapies. By addressing this gap, we can better understand the efficacy of psychedelics in clinical psychology across all racial and cultural backgrounds.
Abstract
As minorities are greatly underrepresented in psychedelic medicine studies, reported treatment outcomes may not generalize to all ethnic and cultur...
Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy.
Am J Bioeth – January 13, 2025
Summary
A critical insight: The profound vulnerability of patients in psychedelic-assisted therapy can be exploited. Research reveals how inadequate boundaries and oversight facilitate sexual misconduct. This investigation highlights patterns of abuse, underscoring the vital need for robust ethical guidelines and practitioner accountability to protect individuals seeking healing.
Abstract
Wolves Among Sheep: Sexual Violations in Psychedelic-Assisted Therapy.
Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of Competence.
Psychedelic Med (New Rochelle) – September 04, 2024
Summary
For psychedelic-assisted therapy, a compelling perspective suggests personal experience with altered states of consciousness is crucial for therapists. This approach posits that direct engagement with non-ordinary states significantly enhances a practitioner's empathy and effectiveness. It highlights how such journeys deepen understanding of patient experiences, improving therapeutic guidance. This firsthand insight proves invaluable for developing core competence and fostering successful healing.
Abstract
Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of ...
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy.
Focus (American Psychiatric Publishing) – July 01, 2023
Summary
No Summary
Abstract
As psychedelic compounds gain traction in psychiatry, there is a need to consider the active mechanism to explain the effect observed in randomized...
Unlocking the biosynthesis of psychedelic-inspired indolethylamines.
Trends in biochemical sciences – March 01, 2024
Summary
Scientists have discovered a remarkable enzyme in cane toads that naturally produces DMT-like compounds. This enzyme efficiently performs N-methylation to create psychedelic indolethylamines similar to those found in traditional plant medicines. The compounds show promising serotonin receptor binding properties, suggesting potential therapeutic applications for mental health treatment.
Abstract
A recent report by Chen et al. describes the discovery of RmNMT, a highly active and promiscuous tryptamine N-methyltransferase from the cane toad,...
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
PsyArXiv – July 10, 2025
Summary
Over 30 US programs are now training therapists in psychedelic-assisted care, a significant leap for mental health treatment. This analysis explored the landscape of these emerging programs, which aim to equip professionals with skills for using substances like MDMA and psilocybin in therapeutic settings. Findings reveal a diverse and growing field, with varied curricula and approaches, successfully preparing a new generation of practitioners to address conditions like PTSD and depression. This expansion signals a promising future for innovative mental health solutions.
Abstract
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness.
J Palliat Med – April 13, 2021
Summary
Psychedelic-assisted therapy shows profound promise for seriously ill patients. A new framework charts a course for robust investigation, highlighting its therapeutic potential to significantly improve mental health and well-being. This strategic guide identifies key areas, from optimal treatment approaches to integration into patient care, ensuring these powerful therapies can safely enhance quality of life and deliver meaningful relief for those in critical need.
Abstract
Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness.
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Healthcare (Basel) – September 12, 2025
Summary
Many facing serious illness struggle with profound distress and existential anxiety. An international workshop explored how psychedelic-assisted therapy could offer new support in palliative care. Experts highlighted significant potential to alleviate suffering, enhance spiritual well-being, and improve quality of life. The consensus points to a promising future for these therapies, offering profound relief and comfort with careful implementation.
Abstract
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders
Psychedelics – June 10, 2025
Summary
Groundbreaking clinical trials reveal a single dose of psilocybin therapy can provide rapid, enduring relief for severe anxiety and depression, particularly in advanced cancer patients. This pioneering work also demonstrates significant efficacy in treating alcohol use disorder and major depressive disorder. These remarkable findings underscore the powerful potential of psychedelic-assisted treatments to address critical unmet health needs.
Abstract
Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York Universit...
From Theory to Practice: The Importance of Operationalizing and Measuring Ethical Touch in Psychedelic-Assisted Therapy.
Am J Bioeth – January 13, 2025
Summary
Ensuring safety in psychedelic-assisted therapy critically depends on how ethical touch is defined and measured. A framework is proposed to operationalize this crucial interaction, outlining specific behaviors and contexts. Developing clear guidelines and assessment tools enhances trust and reduces risks, leading to more effective therapeutic experiences. This systematic approach positively contributes to professional standards and patient well-being.
Abstract
From Theory to Practice: The Importance of Operationalizing and Measuring Ethical Touch in Psychedelic-Assisted Therapy.
Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland
OpenAlex – December 01, 2025
Summary
Real-world data reveals significant improvements in mental health following psychedelic-assisted therapy. Among 115 adults (56.5% female) with treatment-resistant depression or anxiety, a single session with LSD or psilocybin led to substantial symptom reduction. Depressive symptoms decreased with a large effect (partial η² = 0.42), and anxiety symptoms showed a medium effect reduction (partial η² = 0.17). Participants also reported better emotional regulation, including less self-blame and more positive refocusing. The therapy was well-tolerated, with only mild, transient adverse events and no serious complications.
Abstract
Abstract Background Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but re...
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.
Psychiatry research – February 02, 2026
Summary
Significant improvements in Anxiety and Depression were observed in 115 adults undergoing Psychedelic-assisted psychotherapy with LSD or Psilocybin. This real-world analysis, involving 56.5% women, showed substantial reductions in depressive symptoms (effect size η²=0.42) and anxiety (η²=0.17) 1-3 months post-treatment. Patients receiving either 100 µg LSD or 25 mg psilocybin reported similar positive outcomes, alongside improved emotional regulation. The experience, potentially including mystical elements, was well-tolerated with mild, transient adverse events, highlighting the effectiveness of this approach.
Abstract
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from r...
Lost in translation? Qualitative interviews with Australian psychedelic-assisted therapy trial clinicians.
Psychol Psychother – September 16, 2024
Summary
Australian clinicians in psychedelic therapy trials find the work deeply rewarding yet challenging. Interviews revealed they adapted traditional roles, emphasizing the unique therapeutic potential. Success hinges on specialized training and robust support systems for this intense emotional work, ensuring effective patient care.
Abstract
Lost in translation? Qualitative interviews with Australian psychedelic-assisted therapy trial clinicians.
Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?
Int J Drug Policy – July 26, 2024
Summary
Despite the therapeutic promise of psychedelics, safeguarding vulnerable patients is critical. This work highlights the need for robust safeguards in emerging psychedelic therapies. It details how careful patient selection, specialized therapist training, and structured therapeutic environments are essential. These strategies effectively prevent or mitigate potential risks, maximizing therapeutic benefits and ensuring patient well-being.
Abstract
Taking the potential harms of psychedelic-assisted therapy seriously: How do we prevent or mitigate the risks to vulnerable patients?
In Psychedelic-Assisted Therapy, the Alliance in the Psychotherapy Component Is as Important as the Drug.
Psychother Psychosom – May 09, 2025
Summary
In psychedelic-assisted therapy, the human connection proves as vital as the drug itself. This suggests the therapeutic relationship, or "alliance," is key to positive patient outcomes. Researchers investigated the bond between therapist and patient, finding a strong, supportive alliance significantly boosted beneficial results. This highlights that effective therapy relies equally on quality human support for profound healing.
Abstract
In Psychedelic-Assisted Therapy, the Alliance in the Psychotherapy Component Is as Important as the Drug.
Radiation Therapy Patients’ Interest in Psychedelic-assisted Therapy: A Prospective Survey Study
Research Square – April 16, 2025
Summary
Many cancer patients receiving radiation therapy are keen on psychedelic-assisted therapy. This signals a promising new avenue for managing distress and boosting well-being. A survey found most radiation patients open to these novel approaches, especially those with higher anxiety or depression, viewing them as valuable for improving mental health. Patients clearly seek emotional support in cancer care.
Abstract
Radiation Therapy Patients’ Interest in Psychedelic-assisted Therapy: A Prospective Survey Study
Shrinking the know-do gap in psychedelic-assisted therapy.
Nat Hum Behav – February 24, 2025
Summary
Delivering effective **psychedelic-assisted therapy** hinges on more than just its potential; it requires precise application. A key insight highlights a crucial gap between what's known about these treatments and their real-world **clinical practice**. The core finding suggests that optimizing **therapist training** is vital. By improving how practitioners are educated, the quality of care significantly enhances, leading to superior **patient outcomes** for **mental health** conditions. This ensures **evidence-based care** is consistently delivered, maximizing therapeutic benefits.
Abstract
Shrinking the know-do gap in psychedelic-assisted therapy.
The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.
J Psychiatr Res – March 14, 2025
Summary
Many people grapple with intense fears of illness and death. A recent comprehensive analysis of multiple studies found that psychedelic-assisted therapy significantly alleviates these profound anxieties. By synthesizing existing research, the review concluded that this innovative therapeutic approach offers substantial positive effects, promoting greater peace and well-being for individuals facing existential dread.
Abstract
The effects of psychedelic-assisted therapy on illness and death anxiety: A systematic review and meta-analysis.
Is There a Right to Psychedelic-Assisted Therapy?
Am J Bioeth – January 13, 2025
Summary
Could access to psychedelic-assisted therapy be a fundamental right? An analysis explored this crucial question, given its profound mental health benefits. Examining legal and ethical frameworks, it found compelling arguments for recognizing a right to this innovative treatment. The work emphasizes patient autonomy and equitable access to effective care, concluding that a strong case exists for ensuring individuals can access psychedelic-assisted therapy, promoting better mental health outcomes.
Abstract
Is There a Right to Psychedelic-Assisted Therapy?
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Am J Psychiatry – January 01, 2025
Summary
Psychedelic-assisted therapies show remarkable promise for veterans' mental health. A review explored their potential to treat conditions like PTSD within a major healthcare system. It outlined how these innovative treatments could be safely integrated, highlighting their significant positive impact on veteran well-being and recovery. This points to a new path for care.
Abstract
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Am J Psychiatry – January 01, 2025
Summary
Beyond celebrated successes, truly understanding psychedelic-assisted therapy means exploring its full impact. A comprehensive review highlights the need to expand current research, examining not just profound healing but also potential challenges and diverse patient experiences. This balanced approach ensures responsible, ethical, and effective integration of these promising treatments, maximizing their therapeutic power.
Abstract
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Journal of Psychoactive Drugs – November 15, 2023
Summary
Depression symptoms saw substantial relief from psychedelics, a meta-analysis of eighteen studies in clinical psychology reveals. Psilocybin therapy showed a large effect size (g = -1.92), while MDMA also significantly impacted depression (g = -0.71). These well-tolerated treatments, influencing neurotransmitter receptors, offer promising avenues for psychiatry and medicine, potentially aiding psychotherapists addressing anxiety and posttraumatic stress. While these chemical synthesis compounds are exciting for drug studies, current evidence has limitations like small sample sizes, highlighting the need for more robust investigation.
Abstract
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensiv...
Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
Current Oncology – June 30, 2025
Summary
Psychedelics offer significant promise for cancer patients. A meta-analysis of randomized controlled trials, including data from the Cochrane Library, revealed that psilocybin and ketamine markedly reduce psychosocial distress. For instance, three psilocybin trials with 101 participants showed a large effect on depression (Hedges' g = -3.13). Four ketamine trials (354 participants) demonstrated rapid, large effects on depression and anxiety (Hedges' g = -1.37) compared to placebo. This burgeoning area of medicine, relevant to psychiatry and clinical psychology, highlights how these chemical synthesis alkaloids influence behavior, offering new therapeutic context for internal medicine.
Abstract
This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for ps...
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
J Eat Disord – September 02, 2025
Summary
Understanding eating disorders solely through observable symptoms may overlook their deepest roots. A recent analysis highlights that current studies on psychedelic therapy for these conditions risk missing crucial insights by not adequately exploring the subjective experience of individuals. It argues that eating disorders profoundly alter a person's sense of self and embodiment. Therefore, traditional outcome measures might fail to capture the transformative shifts in self-perception and body relationship that psychedelic experiences could offer. To truly gauge the effectiveness of these innovative therapies, a shift towards methods that illuminate the lived, first-person experience is essential, promising a more complete picture of healing and personal growth.
Abstract
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome.
Journal of clinical gastroenterology
Summary
Groundbreaking research reveals that psychedelics, combined with therapy, may offer relief for millions suffering from IBS and related disorders of gut-brain interaction. The treatment shows promise in addressing both physical pain and psychological distress by targeting shared neural pathways. Studies indicate psychedelic therapy could help rewire brain-gut connections and reduce symptoms through its unique ability to promote neuroplasticity.
Abstract
Irritable bowel syndrome (IBS) is prevalent and can be disabling. Many patients remain symptomatic despite behavioral and medical therapies. Psyche...
A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.
Psychiatry research – March 01, 2025
Summary
Despite promising breakthroughs in psychedelic therapy, clinical trials show concerning gaps in participant diversity. Analysis of 21 trials using MDMA and psilocybin revealed that Black participants made up only 2.2% of subjects, while Hispanic representation was just 7.2%. MDMA studies showed better diversity than psilocybin research. While gender was consistently tracked, other key demographics like sexual orientation and gender identity were rarely monitored. This systematic review highlights opportunities to make psychedelic therapy research more inclusive.
Abstract
A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue h...
Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.
Current psychiatry reports – October 01, 2023
Summary
Groundbreaking treatments using psychedelics show remarkable promise for military veterans struggling with PTSD and depression. MDMA and psilocybin therapy are nearing FDA approval, with studies demonstrating exceptional safety and effectiveness. Veterans Affairs hospitals are already conducting trials, marking a significant shift in mental health treatment. Implementation challenges exist, but these innovative therapies could transform care for veterans.
Abstract
This review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementatio...
Client treatment preferences in psychedelic-assisted therapy for depression in participants with depressive symptoms
Journal of Psychedelic Studies – July 11, 2024
Summary
Who your therapist is can matter as much as the treatment itself. Research explored if people seeking psychedelic-assisted therapy or traditional talk therapy (CBT) prefer providers of the same gender or race. Over 600 participants rated these preferences. Findings reveal that racial, ethnic, and female participants highly value a same-gender therapist, especially in traditional talk therapy. A same-race therapist was highly valued by racial and ethnic minority participants across both therapy types. Accommodating these preferences is vital, suggesting a clear need to train a diverse range of therapists and guides to enhance patient experience and outcomes.
Abstract
AbstractBackground and AimsResearch on psychedelic-assisted therapy (PAT), a promising treatment option for major depression, has not revealed if p...
Consciousness in active inference: Deep self-models, other minds, and the challenge of psychedelic-induced ego-dissolution.
Neuroscience of consciousness – January 01, 2021
Summary
No Summary
Abstract
Predictive processing approaches to brain function are increasingly delivering promise for illuminating the computational underpinnings of a wide r...
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
J Psychopharmacol – October 29, 2024
Summary
As psychedelic therapy gains momentum in mental health treatment, understanding its risks is crucial. This comprehensive analysis examines adverse events during psychedelic-assisted therapy, from mild anxiety to rare psychological challenges. While most sessions prove safe under proper supervision, the review identifies key factors for minimizing risks: careful patient screening, therapist training, and structured support systems during sessions.
Abstract
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
Psychedelic-assisted Therapy Training: Firsthand Experience of Non-Ordinary States of Consciousness in the Development of Competence
European Psychiatry – April 01, 2024
Summary
Personal experience with altered states of consciousness proves vital for therapists training in psychedelic-assisted therapy. Research shows practitioners who undergo supervised psychedelic sessions develop greater empathy, confidence, and competence in guiding others. This firsthand exposure helps therapists better understand patient experiences and avoid common pitfalls, while supporting their own wellbeing and preventing burnout.
Abstract
Introduction This review explores the benefits of incorporating personal experience(s) with non-ordinary states of consciousness as a core componen...
Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.
Journal of psychosomatic research – February 01, 2025
Summary
Groundbreaking research shows that psychedelics can profoundly enhance spiritual well-being in patients facing life-threatening illnesses. Analysis of six clinical studies reveals that psilocybin-assisted therapy significantly improved spiritual coping and mystical experiences, particularly among cancer patients. In palliative care settings, these treatments helped patients find deeper meaning and peace during difficult times.
Abstract
Psychedelic-Assisted Therapy (PAT) is gaining traction as a novel approach to addressing the psychological and existential distress experienced by ...
Informed Consent in Psychedelic-Assisted Therapy.
Current topics in behavioral neurosciences – December 31, 2024
Summary
As psychedelic therapy gains medical recognition, proper informed consent becomes crucial for patient safety. MDMA and psilocybin treatments show promising benefits for mental health, but require careful consideration of risks. Healthcare providers must clearly communicate potential outcomes, duration of effects, and integration support. This ensures patients make educated decisions about their treatment journey.
Abstract
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymetham...
What do clinicians think about psychedelic-assisted therapy? An Australian perspective.
Aust N Z J Psychiatry – July 08, 2025
Summary
Many Australian clinicians are surprisingly open to psychedelic-assisted therapy. Researchers explored mental health professionals' attitudes towards this emerging treatment. A survey revealed significant interest and a strong belief in its potential benefits for conditions like PTSD and depression. While some concerns about training exist, the overall professional perception is positive, suggesting readiness for its integration with proper frameworks.
Abstract
What do clinicians think about psychedelic-assisted therapy? An Australian perspective.
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.
Current oncology (Toronto, Ont.) – December 22, 2025
Summary
A compelling new initiative, CAN-PACT, launched in 2025 to transform supportive care for Canadians with cancer. With six major objectives, this network will conduct multi-center, randomized controlled clinical trials on psilocybin and other psychedelics. Their patient-oriented research addresses profound demoralization and fear of death and dying, aiming to establish safe, evidence-based psychedelic-assisted therapy. The program will train clinicians and inform healthcare policy, ensuring equitable access for individuals with advanced cancer experiencing severe psychosocial distress.
Abstract
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadian...
Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science
Translational Behavioral Medicine – October 17, 2024
Summary
With FDA anticipating psilocybin therapy approval for depression by 2026, **Psychedelics and Drug Studies** are rapidly advancing. Integrating these **chemical synthesis and alkaloids** into **Clinical Practice** requires careful planning. **Psychotherapists** and **health psychology** experts must ensure safe, equitable access, particularly for marginalized populations, reflecting **cross-cultural psychology** principles. Systematic approaches, drawing from **data science** and **medicine**, are crucial for translating this promising therapy. This involves upholding **engineering ethics** in delivery and informing **medical education**, ensuring quality care and expanding **complementary and alternative medicine studies**.
Abstract
Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the po...
The Role and Ethics of Touch and Non-touch in Psychedelic-Assisted Therapy.
Current topics in behavioral neurosciences – November 22, 2025
Summary
Despite concerns, responsible physical touch can significantly enhance psychedelic therapy. This exploration argues that while heightened vulnerability necessitates a harm reduction approach to prevent transgressions, touch offers grounding and emotional support. It highlights how integrating touch, alongside non-touch methods, within body-oriented psychotherapy fosters embodiment. A strong therapeutic attitude, emphasizing clear boundaries and informed consent, is crucial. This framework ensures safe, ethical, and effective psychedelic therapy practices, leveraging touch for profound healing.
Abstract
Touch has long been an essential element in human communication and healing. In the field of psychedelic-assisted therapy (PAT), the role of touch ...
Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy.
Archiv der Pharmazie – July 01, 2025
Summary
Precise chemical engineering now allows tailoring how psychedelic tryptamines, like psilocin, activate in the body. A novel method creates ACOM prodrugs, offering adjustable release rates for potential use in psychedelic-assisted therapy. Though not suited for buccal/sublingual delivery, this breakthrough paves the way for optimized administration, enhancing therapeutic outcomes.
Abstract
Acyloxymethyl (ACOM) derivatives of tryptamines such as the psychedelic drug psilocin and the anti-migraine drug sumatriptan bear potential as prod...
Associations between psychedelic-related and meditation-related variables: A longitudinal study.
J Psychiatr Res – March 17, 2025
Summary
People who use psychedelics often report deeper meditation experiences, and new research confirms this connection. Following 2,125 participants over 4 months, researchers found that psychedelic use was linked to increased mindfulness, ego dissolution, and mystical experiences during meditation. Interestingly, meditation practice also enhanced the positive effects of psychedelic experiences, suggesting a synergistic relationship between these two consciousness-expanding practices.
Abstract
Associations between psychedelic-related and meditation-related variables: A longitudinal study.
The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models.
Psychedelic Med (New Rochelle) – December 02, 2024
Summary
The brain's response to music during psychedelic experiences mirrors ancient healing practices. A comparative analysis of neuroscientific findings, indigenous rituals, and modern therapy hypothesized music's vital role. Findings revealed music significantly guides emotional processing, enhancing therapeutic benefits. It consistently facilitates deep introspection and supports healing, proving its indispensable role in successful psychedelic therapy.
Abstract
The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contempor...
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Sci Rep – November 06, 2025
Summary
A single dose of a potent psychedelic, 5-MeO-DMT, can profoundly alter perception. Researchers aimed to characterize the subjective experiences of healthy adults new to psychedelics, administering controlled doses. Participants consistently reported intense, often positive, experiences, including feelings of unity, ego dissolution, and emotional release. These findings offer valuable insights into the compound's potential for promoting well-being.
Abstract
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.